Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $37.0 million.

  • C4 Therapeutics' Current Deferred Revenue fell 2509.87% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 2509.87%. This contributed to the annual value of $47.2 million for FY2024, which is 2650.93% up from last year.
  • Latest data reveals that C4 Therapeutics reported Current Deferred Revenue of $37.0 million as of Q3 2025, which was down 2509.87% from $43.8 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Current Deferred Revenue registered a high of $56.2 million during Q4 2021, and its lowest value of $26.6 million during Q1 2021.
  • Moreover, its 5-year median value for Current Deferred Revenue was $37.3 million (2023), whereas its average is $39.6 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 10348.51% in 2021, then plummeted by 4033.44% in 2022.
  • Quarter analysis of 5 years shows C4 Therapeutics' Current Deferred Revenue stood at $56.2 million in 2021, then crashed by 40.33% to $33.5 million in 2022, then rose by 11.26% to $37.3 million in 2023, then rose by 26.51% to $47.2 million in 2024, then decreased by 21.53% to $37.0 million in 2025.
  • Its Current Deferred Revenue was $37.0 million in Q3 2025, compared to $43.8 million in Q2 2025 and $46.7 million in Q1 2025.